der the Paperwork Reduction Act of 1995, no	persons are re			IS ON B CONTROL HOMBER.
TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	08/974,584	<u> </u>
		Filing Date	November 19, 1997	RECE
		First Named Inventor	Cech et al.	11111
		Group Art Unit	1655	JUN 1
		Examiner Name	Myers, Carla J.	TECH CENTE
otal Number of Pages in This Submission	1	Attorney Docket Number	15389002950	TECH CENTS
	ENCL	OSURES (check all that apply)		
Fee Transmittal Form	Assignment Papers (for an Application)		After Allowance C	ommunication to
Fee Attached	☐ Drawing(s)		Appeal Communication to Board of Appeals and Interferences	
Amendment / Response	Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
After Final	Petition Routing Slip (PTO/SB/69) and Accompanying Petition		Proprietary Information	
Affidavits/declaration(s)	Petition to Convert to a Provisional Application		Status Letter	
Extension of Time Request	Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(
Express Abandonment Request	1=	nal Disclaimer est for Refund	Communication Und 1.825 and Amendme Sequence Listing in computer readable	ent; Substitute hard copy and
Information Disclosure Statement	CD, Number of CD(s)		to Comply	
Certified Copy of Priority Document(s)	Rem		is authorized to charge an- -1430.	ly additional fees to
Response to Missing Parts/ Incomplete Application				
Response to Missing Parts under 37 CFR	;			

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EL801719356 US addressed to: Box Sequence, Assistant Commissioner for Patents, Wpshington, D.C. 20231 on this date; June 8, 2001

Typed or printed name

Maisie C. Livengood

June 8, 2001

Signature

Date

Date

June 8, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. DE 7042380 v1

RECEIVED

Application No.: 08974,584 JUN 15 2001 NOTION OF THE PROPERTY **DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

nents for such a disclosure as sectional in or
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825.
Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a
"Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by
37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of
37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
A williams Must Provide:
Applicant Must Provide: ✓ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or
1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216
For CRE Submission Help. Call (703) 306-4212
For Patentin software help, call (703) 300-0000
TO THE NOTICE WITH YOUR RESPONSE

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Express Mail" Label No. EL 8017193 US
Date of Deposit: June 8, 2001

hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under TR 1.10 on the date indicated above and is addressed to:

JUN 0 8 2000 ssist nt Commission for Patents Washington, DC 20231

& TRADE

NISEND and TOWNSEND and CREW LLP

By: A

Attorney Docket No.: 015389-002950US Client Reference No.: 18/206P2

RECEIVEDA

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CECH et al.

Application No.: 08/974,584

Filed: November 19, 1997

For: TELOMERASE REVERSE

TRANSCRIPTASE

Examiner:

Myers, Carla J.

Art Unit:

1655

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

<u>AND</u>

AMENDMENT

Box SEQUENCE Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed May 10, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

In the Specification:

Please cancel the present "SEQUENCE LISTING", pages 1-284, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 284, at the end of the application.